Imatinib mesylate

甲磺酸伊马替尼

Report date: 2026/05/06 20:02:28
NMEFirst In Class

Base Information

Drug NameImatinib mesylate
Drug Alias NameImatinibum甲磺酸伊玛替尼伊马替尼甲磺酸盐Imatinib mesilateImatinib inhalation - Aerami Therapeutics +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsBcr-Abl tyrosine kinase inhibitorsStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptorBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Diabetic macular oedemaCoronavirus Disease 2019 (COVID-19) +[130] 
Global Approved IndicationsChronic eosinophilic leukemia (CEL)Hypereosinophilic SyndromeGastrointestinal Stromal Tumors +[5] 
Approved Indications in ChinaGastrointestinal Stromal TumorsLeukemia, Myelogenous, Chronic
Original Approved Country/TerritoryUnited States
Original Approved Date2001/05/10
Country/TerritoryBelgiumCanadaUnited States +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute For Health Research, United KingdomVictoria Biomedical Research InstituteShorla Oncology Inc +[12] 
Inactive CompaniesDana-Farber Cancer InstituteRadboud University Medical CenterUniversity Of California San Francisco +[38] 
Active IndicationsChronic eosinophilic leukemia (CEL)Hypereosinophilic SyndromeMyelodysplastic Syndromes +[14] 
Inactive IndicationsDiabetic macular oedemaCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[116] 

Other Information

ATC CodeL01EA01
Related LinksWikipediaDrugBankKEGG